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This month, in lieu of an Editor’s Page, the editors of JACC
introduce a new feature that will occur annually. The editors
have each summarized articles published in JACC that are of
particular significance clinically or with regard to research.
These papers represent the highlights of the past 12 months
in JACC, as selected by the editors. We believe that these
manuscripts represent important emerging areas in cardiol-




Three themes emerged in reports addressing coronary artery
disease (CAD) and myocardial infarction (MI) in the pages
of the Journal over the past year: 1) the role of inflammation
and the value of C-reactive protein (CRP); 2) the refine-
ment of risk assessment both in chronic and acute coronary
disease; and 3) the improvement of current therapy, both
validating new pharmacologic approaches and implement-
ing proven therapies.
Inflammation. Inflammation has now been recognized as
playing a central role in atherosclerosis and endothelial
dysfunction. Emerging evidence points to CRP not only as
a marker of disease, but also playing a causal role in
endothelial dysfunction and atherogenesis. A study by
Cosin-Sales et al. (1) extended the role of CRP as a marker
of CAD to patients with chest pain and normal coronary
angiograms. Although some of these patients have non-
cardiac causes of chest pain, endothelial dysfunction may
play an important role in the pathogenesis of syndrome X.
Cosin-Sales et al. (1) reported on 137 patients with chest
pain and normal coronary angiograms. High-sensitivity
C-reactive protein (hs-CRP) levels were higher in patients
with frequent and prolonged chest pain episodes, as well as
in those with ST-segment depression on Holter monitoring
and exercise testing. Moreover, hs-CRP was the only
independent variable predictive of positive Holter and
exercise test findings. Thus, hs-CRP may assist in the
diagnosis of syndrome X patients and further substantiates
the role of inflammation in this entity.
Biomarkers. The field of biomarkers continues to evolve
rapidly, with new data not only on acute coronary syndrome
but also on other cardiovascular diseases. A study by
Landesberg et al. (2) illustrated the power of newer gener-
ation troponin assays and creatine kinase-MB isoenzyme to
risk-stratify patients undergoing major vascular surgery. In a
cohort of 447 consecutive patients, they found that even
minor elevations of troponin and creatine kinase-MB isoen-
zyme were potent risk predictors. Patients having elevations
in one marker had a two- to three-fold risk of mortality.
Patients with elevation of both markers had a 4.19-fold
increase in long-term mortality. Most importantly, although
24% of patients had elevations in biomarkers, only 3.6%
presented with symptoms and only 5.6% met previous
World Health Organization criteria for MI.
Renal insufficiency. The effect of renal insufficiency on
cardiovascular risk was the subject of numerous articles,
increasing our awareness of the importance of renal dys-
function in cardiology. In a retrospective study utilizing data
from the Thrombolysis In Myocardial Infarction (TIMI)-
10, TIMI-14, and Intravenous nPA for Treatment of
Infarcting Myocardium Early (InTIME)-2 trials, Gibson et
al. (3) demonstrated that 30-day mortality in ST-segment
elevation myocardial infarction (STEMI) patients increased
stepwise with increasing creatinine levels and impaired
creatinine clearance, independent of other conventional risk
factors and the TIMI risk score. An independent contribu-
tion of renal dysfunction, after controlling for CRP and the
extent of CAD, was also found in a study by Zebrack et al.
(4) of patients without MI. In their study of 1,484 patients
who underwent angiography and were followed for a mean
of three years, renal insufficiency was associated with unad-
justed hazard ratios of 2.3 for death/MI and 5.4 for renal
failure. Adjustment for CRP, CAD score, and all other risk
factors had a minimal or modest impact on the risk,
indicating that renal insufficiency is an independent predic-
tor. Although the underlying mechanism of this increased
risk is uncertain, clinicians will need greater awareness of
renal dysfunction in the assessment of the cardiac patient.
Indeed, in a related report, Berger et al. (5), using the
End-Stage Renal Disease and Cooperative Cardiovascular
Project databases, documented that patients with end-stage
renal disease were less likely to be treated with aspirin,
beta-blockers, and angiotensin-converting enzyme inhibi-
tors during admission for acute MI, yet the benefit of these
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simple interventions appeared to be maintained compared
with patients without end-stage renal disease.
Pharmacologic therapy of acute MI. The search for new
therapies in MI continue to generate intense study. With
the advent of glycoprotein (GP) IIb/IIIa inhibitors and the
recognition that platelets play a key role in MI, it was hoped
that combination therapy with reduced-dose lytic and GP
IIb/IIIa inhibition would improve reperfusion therapy. The
Integrilin and Tenecteplase in Acute Myocardial Infarction
(INTEGRITI) phase II angiographic trial (6) examined the
role of eptifibatide in combination with different tenect-
eplase doses. Patients randomized to combination therapy
tended to have more TIMI 3 flow grade, arterial patency,
and ST-segment resolution, but also more major hemor-
rhage and transfusions. The investigators concluded that
further study was necessary before this combination therapy
could be recommended for general use.
Glucose-insulin-potassium, an “old” therapy advocated
since the early 1960s, was the subject of a clinical trial, the
largest such trial reported to date and the first in patients
treated with primary percutaneous transluminal coronary
angioplasty (7). When infused over 8 to 12 h, glucose-
insulin-potassium was studied in an open-label trial of 940
patients undergoing percutaneous transluminal coronary
angioplasty for STEMI. Overall, there was a trend toward a
mortality reduction at 30 days: 4.8% in the glucose-insulin-
potassium group versus 5.8% in the control group. In 856
patients without heart failure (HF) on presentation, there
was a significant reduction in mortality from 4.2% to 1.2%.
The lack of benefit in patients who presented with HF may
be related to the large volume load given in the study.
Although further studies are clearly needed, the results of
this trial emphasized the potential of metabolic interven-
tions to improve therapy in acute MI.
INTERVENTIONAL CARDIOLOGY
Primary percutaneous coronary intervention (PCI) with
adjunctive GP IIb/IIIa inhibitors. The use of GP IIb/
IIIa inhibitors in primary PCI is controversial. The trial
reported by Antoniucci et al. (8) randomized 400 patients
with acute STEMI to infarct-related artery stenting plus
abciximab or stenting alone. The primary end point (com-
posite of death, reinfarction, target vessel revascularization,
and stroke at one month) was lower in the abciximab/
stenting group compared with the stenting alone group
(4.5% vs. 10.5%, p  0.023). This was also associated with
faster ST-segment resolution, improved left ventricular
(LV) function at one month, and improved mortality at six
months (5.5% vs. 13.5%, p  0.006). Bleeding complica-
tions were similar among groups.
As Topol et al. (9) point out in an accompanying
editorial, pooling the data from this trial and four previous
trials addressing this issue (RePro in Acute myocardial
infarction and Primary PTCA Organization and Random-
ized Trial [RAPPORT], Intracoronary Stenting and Anti-
thrombotic Regimen [ISAR]-2, Abciximab before Direct
Angioplasty and stenting in Myocardial Infarction Regard-
ing Acute and Long-term followup [ADMIRAL], and
Controlled Abciximab and Device Investigation to Lower
Late Angioplasty Complications [CADILLAC]) resulted
in an overall 46% reduction in death, reinfarction, and target
vessel revascularization, a 34% reduction in death or rein-
farction, and a 26% reduction in death, providing strong and
consistent evidence of a benefit for adjunctive use of
abciximab with catheter-based reperfusion for MI.
Daytime versus nighttime primary PCI. It is unclear
whether the benefits of PCI are comparable for nighttime
and daytime. Henriques et al. (10) evaluated the impact of
circadian patterns in the onset and treatment of STEMI on
the outcomes of primary angioplasty in 1,702 consecutive
patients. They observed circadian variation in frequency of
symptom onset, hospital admission, and first balloon infla-
tion, with the majority of patients (52%) presenting and
having PCI during routine duty hours. There were no
differences in baseline clinical characteristics or treatment
delays between patients treated during routine duty hours
(8 AM to 6 PM) and off-hours (6 PM to 8 AM). However,
daytime hospital admission was associated with a lower
angioplasty failure rate (3.8% vs. 6.9%, p  0.01) and
30-day mortality (1.9% vs. 4.2%, p  0.01), compared with
nighttime hospital admission. The authors postulated several
explanations for these findings, including different patient
characteristics, improved care during the daytime, and possibly
increased resistance of fibrinolyis and prothrombotic tenden-
cies in the evening due to circadian mechanisms. This intrigu-
ing observation was editorialized by Spencer and Becker
(11), who suggested that much of this effect may be due to
baseline patient characteristics (i.e., patients with HF may
present in a circadian pattern and more often in the
evening), differences in health-seeking behavior or health
care delivery, and physician availability. With the increasing
use of primary PCI, these findings warrant further research,
as the public health impact is very significant.
Facilitated PCI. Recent studies have shown a superiority
of primary stenting over thrombolytics in STEMI patients.
However, it was uncertain whether rapid transfer to a
PCI-capable hospital was beneficial to patients arriving at a
hospital without PCI facilities. The Streptokinase in Acute
Myocardial Infarction (SIAM III) study by Scheller at al.
(12), was a multicenter, randomized, prospective, controlled
trial including 163 patients receiving thrombolysis during
STEMI. One cohort was transferred within 6 h after
thrombolysis for catheterization and PCI, whereas the other
group received elective coronary angiography at two weeks
after initial thrombolysis and, if indicated, stenting of the
infarct-related artery. Immediate stenting after thrombolysis
was associated with a significant reduction in the combined
end point after six months (ischemic events, death, reinfarc-
tion, target lesion revascularization; 25.6% vs. 50.6%, p 
0.001), despite a 23% crossover in the thrombolysis only
group. There was an improvement in LV function at six
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months. However, there was an 8.6% risk of major bleeding
and a 2.4% incidence of stroke. No difference in mortality
was noted, but the trial was not powered for this end point.
This trial complements the findings of previous trials, such
as DANish trial in Acute Myocardial Infarction
(DANAMI-2), PRimary Angioplasty in patients trans-
ferred from General community hospitals to specialized
PTCA Units with or without Emergency thrombolysis
(PRAGUE), and AIR-PAMI, showing improved outcomes
in patients transferred to a specialized center for facilitated
PCI. As McKay (13) points out in an accompanying
editorial, only 25% of hospitals in the U.S. and 10% in
Europe can offer PCI, and there is often a significant time
delay in transferring patients for PCI. Although this study
has the limitations of a prolonged delay in reperfusion and
a substantial bleeding risk and is underpowered for hard
events, the approach of facilitated PCI is viable but requires
additional studies “to end the long-standing debate about
the relative superiority of pharmacologic over mechanical
intervention, so that we can move forward in an attempt to
find an even better reperfusion option.”
Do GP IIb/IIIa inhibitors prevent mortality? Although
GP IIb/IIIa inhibitors reduce post-PCI cardiac enzyme
elevations, previous studies were not powered to show a
benefit in overall mortality. In a meta-analysis of all PCI
trials using GP IIb/IIIa inhibitors, including over 20,000
patients, Karvouni et al. (14) showed that GP IIb/IIIa
inhibitors decreased the risk of death at 30 days and up to 1
year (21% relative risk reduction, p  0.008). This risk
reduction was independent of clinical presentation, PCI
approach (stent vs. balloon), or use of postprocedural
heparin. Major bleeding was significantly increased only in
trials where heparin was continued after the procedure.
Although this study has all the limitations of a meta-
analysis, it does suggest that GP IIb/IIIa inhibitors may
have a beneficial effect on mortality in PCI.
Treatment of in-stent restenosis (ISR). BALLOON ANGIO-
PLASTY VERSUS REPEAT STENTING FOR ISR. Coronary
brachytherapy is not widely available worldwide to treat all
patients with ISR (estimated at 150,000 per year in the
U.S.) and has certain regulatory and technical limitations.
To evaluate alternative strategies to treat ISR, Alfonso et al.
(15) performed the first randomized clinical trial comparing
repeat stenting with conventional balloon angioplasty in
patients with ISR. They randomly assigned ISR patients to
stent implantation (n  224) or conventional balloon
angioplasty (n  226). The primary end point—recurrent
restenosis rate at six months—was similar (38% to 39%), as
was one-year event free survival, despite a larger postproce-
dural minimum lumen diameter in the stenting group (2.77
vs. 2.25 mm, p  0.001). Prespecified subgroup analyses in
large vessels (3 mm) showed a reduced restenosis rate
(27% vs. 49%, p  0.007) and improved event-free survival
(84% vs. 62%, p  0.002) in the repeat stenting group,
largely due to a reduced need for repeat interventions. The
authors conclude that in patients with ISR, repeat coronary
stenting provides better initial angiographic results but
failed to improve the restenosis rate and clinical outcome, as
compared with conventional balloon angioplasty. However,
in patients with large vessels, coronary stenting improved
the long-term clinical and angiographic outcome.
CONVENTIONAL BALLOON ANGIOPLASTY VERSUS CUTTING
BALLOON ANGIOPLASTY FOR ISR. To compare cutting bal-
loon angioplasty with conventional balloon angioplasty,
Albiero et al. (16) reported the REStenosis CUtting balloon
evaluation Trial (RESCUT), a multicenter, randomized,
prospective study that enrolled 428 patients with all types of
ISR (focal, multifocal, diffuse, or proliferative). At seven-
month follow-up, there was no difference between the
groups in angiographic binary restenosis rate (cutting bal-
loon angioplasty 29.8%; conventional balloon angioplasty
31.4%), pattern of recurrent restenosis, and clinical events.
However, cutting balloon angioplasty was associated with
some procedural advantages over conventional balloon an-
gioplasty, such as use of fewer balloons, less requirement of
additional stenting, and lower incidence of balloon slippage.
SIROLIMUS-ELUTING STENTS FOR ISR. This small observa-
tional study from the Thoraxcenter by Degertekin et al. (17)
reports the first human experience with drug-eluting stents
for ISR. One or more sirolimus-eluting stents were im-
planted in 16 patients with severe, recurrent ISR in a native
coronary artery and with objective evidence of ischemia.
Quantitative angiographic and three-dimensional intravas-
cular ultrasound follow-up performed at four months
showed four patients (25%) with recurrent restenosis. Clin-
ical follow-up at nine months revealed that three patients
had experienced four major adverse cardiac events (two
deaths and one acute MI necessitating repeat target vessel
angioplasty).
These studies on the treatment of ISR show that repeat
stenting and cutting balloon angioplasty for ISR do not lead
to an overall reduction in dichotomous angiographic reste-
nosis or major adverse cardiac events; therefore, their use
will find niche applications such as balloon slippage, inad-
equate angiographic results, or restenosis in very large
vessels. Pending further studies, coronary brachytherapy
appears to be the best initial modality for the initial episode
of ISR, although the jury is out for recurrent ISR.
Appropriate hospital volumes for PCI. Significant debate
has taken place over the past decade regarding the appro-
priate volumes of PCI for both interventional cardiologists
and hospitals. The American College of Cardiology
(ACC)/American Heart Association (AHA)-proposed
guidelines recommend a minimum of 400 procedures for
hospitals that offer PCI. Krumholz et al. (18) conducted a
retrospective analysis of the Agency for Healthcare Research
and Quality nationwide inpatient sample hospital discharge
database to evaluate in-hospital mortality among patients (n
 362,748) who underwent PCI between 1998 and 2000 at
low (5 to 199 cases/year), medium (200 to 399 cases/year),
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high (400 to 999 cases/year), and very high (1,000
cases/year) PCI-volume hospitals.
An inverse association was found between hospital PCI
volume and in-hospital mortality (2.56%, 1.83%, 1.64%,
and 1.36% at low-, medium-, high-, and very-high-volume
hospitals, respectively; p  0.001 for trend). After multi-
variate adjustment, patients at low-volume hospitals re-
mained at increased risk (odds ratio 1.21, 95% confidence
interval 1.06 to 1.28), whereas patients at medium- and
very-high-volume hospitals had a comparable mortality risk.
The study lacked angiographic information to relate to
procedural risk, data on whether low-volume hospitals
referred high-risk cases to high-volume centers, and data on
the outcomes of individual physicians. The authors suggest
a re-evaluation of the ACC/AHA guidelines regarding the
minimum standards required for hospitals performing PCI,
which will have major implications on the number of
hospitals able to provide PCI to their patients.
NONINVASIVE CARDIOLOGY
Strain rate and backscatter imaging in diabetes. Although
abnormalities in contractile performance have been recorded
in asymptomatic diabetics, the potential contribution of
co-existing hypertension or CAD to these findings remains
uncertain. Therefore, Fang et al. (19) studied 186 patients
with a normal ejection fraction and no evidence of CAD: 48
patients with diabetes only, 45 patients with LV hypertro-
phy only, 45 patients with both diabetes and LV hypertro-
phy, and 48 normal controls. Measurements of peak strain
and strain rate derived from Doppler tissue imaging dem-
onstrated impaired systolic function compared with controls
in all groups; values were lowest in the group with both
diabetes and hypertrophy. Integrated backscatter imaging
revealed increased intensity levels in all patient groups
compared with controls. Thus, this study documented the
existence of impaired myocardial performance in diabetics,
even in the absence of hypertension/hypertrophy and coro-
nary disease. Moreover, it demonstrated the sensitivity of
strain rate imaging in detecting abnormal myocardial per-
formance, even in the setting of normal LV structure and
ejection fraction.
Flow-mediated brachial artery dilation. It is now recog-
nized that coronary atherosclerosis is very prevalent in
patients with peripheral vascular disease and is likely to
result in adverse events either with surgical interventions or
during long-term follow-up. To further identify patients
with peripheral vascular disease at risk of coronary events,
Gokce et al. (20) assessed endothelial function by measuring
changes in flow-mediated brachial artery diameter by ultra-
sound in approximately 200 patients with peripheral artery
disease scheduled for vascular surgery. This study demon-
strated that endothelium-dependent flow-mediated dilation
was significantly lower in the 35 of 199 patients who
experienced an event over a 15-month follow-up than in
those who did not (4.4% vs. 7.0%, p  0.001). In fact,
abnormal endothelial function was one of three independent
risk factors in addition to older age and more invasive
surgery for cardiac events. Thus, this study established that
impaired endothelial function, as delineated by ultrasound
measurements of brachial artery diameter, identified pa-
tients with peripheral vascular disease who were at risk of a
coronary event and who might benefit by more intensive
management.
Integrated backscatter analysis in muscular dystrophy.
Although congestive HF is common in the late stages of
Duchenne’s muscular dystrophy, the onset of myocardial
abnormalities in this entity remains uncertain. Therefore,
Giglio et al. (21) assessed integrated myocardial backscatter
by means of acoustic densitometry in 20 patients with
Duchenne’s muscular dystrophy compared with age-
matched normal subjects. They observed that cyclic varia-
tion of integrated backscatter was reduced in the muscular
dystrophy patients (4.4 vs. 8.8 dB), whereas total integrated
backscatter values were increased. These data demonstrate
that myocardial abnormalities occur early in the course of
Duchenne’s muscular dystrophy and antedate any evidence
of impaired LV ejection fraction. The study provides im-
portant evidence of the ability of acoustic integrated back-
scatter analysis to detect subclinical abnormalities of the
myocardium. As pointed out by Towbin (22) in an accom-
panying editorial, since all patients with dystrophin defi-
ciency are at risk for the development of dilated cardiomy-
opathy (DCM), they are candidates to be screened by this
type of noninvasive technique. Moreover, ultrasonic find-
ings could conceivably provide an end point for assessing the
value of drug therapy in these patients.
Echocardiographic findings after mediastinal irradiation.
Although a variety of cardiovascular complications are
known to follow mediastinal irradiation, particularly when
administered for Hodgkin’s disease, the prevalence and
nature of cardiac abnormalities in asymptomatic patients
after irradiation is unknown. Heidenreich et al. (23) studied
this question by performing standard transthoracic echocar-
diography in 294 asymptomatic patients, many of whom
had received mediastinal irradiation for Hodgkin’s disease
over 20 years before evaluation. Compared with patients
who had been irradiated 10 years earlier, patients treated
20 years earlier had a greater incidence of aortic regurgi-
tation (62% vs. 4%), moderate or greater mitral regurgita-
tion (6% vs. 2%), and aortic stenosis (16% vs. 0%). More-
over, in comparison to a control population from the
Framingham Heart Study, more patients manifested re-
duced LV shortening, and the group exhibited a lower LV
mass. These data demonstrate that cardiac abnormalities are
very prevalent in asymptomatic patients who have received
at least 35 Gy of mantle radiation, and that such abnormal-
ities are more common over time. As pointed out in an
accompanying editorial by Byrd (24), the valvular regurgi-
tation and reduced LV function and mass observed in this
study raise the question as to whether treatment with
prophylactic antibiotics and angiotensin-converting enzyme
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inhibitors should be attempted in these patients. Despite
the assumed resistance of cardiac structures to radiation
therapy, this report documents that newer methods of
irradiation are necessary to protect the heart and great
vessels.
Left atrial appendage obliteration to reduce thromboem-
bolism. The potential benefit of left atrial obliteration in
patients with atrial fibrillation (AF) who have contraindi-
cations to warfarin remains controversial. In the past year,
two studies addressed this problem. Garcia-Fernandez et al.
(25) evaluated the value of ligation of the left atrial append-
age in patients undergoing mitral valve replacement/repair.
The left atrial appendage was ligated in 58 of 205 patients.
During a median time from surgery of 69 months, 27
patients had an embolic event for which the absence of left
atrial appendage ligation or the presence of left atrial
thrombus was the only independent predictor. Furthermore,
when the absence of left atrial appendage ligation was
considered in combination with evidence of incomplete
closure identified by transesophageal echocardiography, the
risk of embolism increased approximately 12 times. These
data attest to the role of the left atrial appendage in systemic
embolization, the value of ligation, and the role of trans-
esophageal echocardiography in detecting incomplete clo-
sure. In patients with AF who are not candidates for
warfarin therapy, a new thorascopic approach to obliteration
of the left atrial appendage was described by Blackshear et
al. (26). Using either a loop snare or stapler, these investi-
gators obliterated the left atrial appendage without thora-
cotomy in 14 of 15 patients. Two strokes were observed in
these patients after a mean follow-up of 42 months. Thus,
this thorascopic approach warrants further evaluation as an
alternative therapy to reduce thromboembolism in AF
patients in whom warfarin is contraindicated. As pointed
out in an accompanying editorial by Halperin (27), patients
with AF often have many potential sources of systemic
emboli. These studies provide evidence that left atrial
appendage remains a likely cause for emboli in such pa-
tients, and that a variety of interventions may be of value in
preventing these events.
HEART FAILURE/HEART TRANSPLANTATION
Implementation of clinical trial results. The Randomized
ALdactone Evaluation Study (RALES) (28) showed that
adding spironolactone to standard therapy could improve
survival in some HF patients. To determine how the results
of RALES were being translated into clinical practice,
Bozkurt et al. (29) evaluated spironolactone use at a large
VA Hospital immediately after release of the RALES
results. They found that spironolactone was initiated in
many patients who had less severe HF or more severe renal
dysfunction than did the patients in RALES, and that
follow-up measurements of serum potassium levels were less
frequent in practice than in the trial. Furthermore, patients
at their hospital experienced a considerably higher incidence
of hyperkalemia than did the patients in RALES. These
results imply that patients with less severe HF (who might
not derive as much benefit as the RALES population) were
exposed to the same (or greater, in the case of renal
dysfunction patients) risk as RALES patients, and that the
potentially serious adverse effects of spironolactone therapy
were not given as much attention as the beneficial ones. In
an accompanying editorial, Tang and Francis (30) com-
mented that the trial results from a carefully defined
population may be inappropriately translated into the gen-
eral population, and that problems remain in disseminating
information from clinical trials to practicing physicians.
Post-transplant hypertension. Hypertension is a frequent
and often difficult-to-treat problem after heart transplanta-
tion. Although a number of factors probably contribute to
the development of this condition, the mechanism(s) in-
volved are poorly understood. In an elegant study, Braith et
al. (31) found that the diuretic and natriuretic response to a
volume load is blunted in transplant recipients due to an
inability to suppress the activity of the renin-angiotensin-
aldosterone system. As noted in the accompanying editorial
by Eisen (32), these results imply that the use of
angiotensin-converting enzyme inhibitors and salt restric-
tion should be particularly effective in treating hypertension
after heart transplantation.
Post-infarct remodeling. Post-MI LV remodeling ad-
versely affects cardiac function and is recognized as a major
cause of HF. The role of cardiac myocyte apoptosis in the
development of structural changes and HF during post-MI
remodeling was assessed by Abbate et al. (33) in a postmor-
tem study of the hearts of 14 patients who died late after
acute MI. The investigators found that the rate of apoptosis
at both the infarct site and in noninfarcted segments of
myocardium correlated significantly with measures of unfa-
vorable LV remodeling. As noted by Mani and Kitsis (34),
this report suggests that continued apoptosis of cardiac
myocytes may play an important role in post-MI remodel-
ing and the transition to HF. These results imply that
anti-apoptotic therapies may prove useful in preventing HF,
and this report will help provide a baseline for future studies
in this area.
Beta-blocker therapy. Although beta-blocking agents
have now been established as standard therapy for HF due
to systolic dysfunction, the value of this approach for HF
complicated by renal dysfunction requiring dialysis is un-
known. Cice et al. (35) reported the results of a placebo-
controlled trial of carvedilol treatment in 114 patients with
DCM on dialysis. They found that carvedilol was associated
with significant attenuation of pathologic LV remodeling,
and that there were significantly fewer deaths and hospital-
izations in patients receiving active drug compared with
placebo. These results provide a rationale for the initiation
of carvedilol therapy in HF patients requiring dialysis.
Nutrition and HF. Reduced physical activity is character-
istic of patients with HF. To determine whether inadequate
nutrition might contribute to this important problem, Aq-
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uilani et al. (36) assessed the nutritional intake in lean
patients with HF compared with matched controls. From a
seven-day diary, they found that the HF patients had a
negative caloric and nitrogen balance compared with con-
trols, and that energy availability in HF patients was
significantly lower. Thus, HF patients may have reduced
energy available for physical activities, and this may con-
tribute to the exercise limitation seen in this condition. In
an accompanying editorial, Silver (37) notes that although
HF patients are given frequent advice about salt intake, little
attention has been paid to the mechanisms responsible for
and the clinical consequences of inadequate nutritional
intake. Because poor nutrition, impaired absorption across
the intestinal wall, and increased metabolic demands may all
be present in HF patients (in particular, those patients with
more advanced disease), greater attention to these issues is
clearly warranted by clinicians and researchers alike.
Left lateral decubitus avoidance. To assess whether avoid-
ance of the left lateral decubitus position occurs in HF and
to provide insight into the mechanisms responsible, Leung
et al. (38) extensively studied a group of 75 HF patients and
a comparable control group using nocturnal polysonogra-
phy. Heart failure patients also underwent echocardio-
graphic and right heart catheterization studies. Compared
with control subjects, the HF patients spent significantly
less time on their left side, which was accentuated in
patients with a larger heart size and evidence of more
severely compromised hemodynamic parameters. These re-
sults confirm that HF patients avoid lying on their left side
and suggest that this preference is related to chest wall
discomfort due to an increased heart size or further hemo-
dynamic or autonomic compromise brought on by the left
lateral decubitus position.
ELECTROPHYSIOLOGIC DISORDERS
Risk stratification in asymptomatic Wolff-Parkinson-
White (WPW) syndrome. To risk-stratify patients with
WPW syndrome, Manguso et al. (39) performed electro-
physiologic studies in 212 consecutive asymptomatic pa-
tients with WPW syndrome, 162 of whom underwent a
second electrophysiologic study at five years. At the electro-
physiologic study, 115 patients had no inducible arrhyth-
mia, whereas 47 patients were inducible. Of the 115 patients
with no inducible arrhythmia, only 3.4% became symptom-
atic. Of the 47 patients who were inducible at the follow-up
electrophysiologic study, 29 patients developed symptom-
atic arrhythmias, 8 of whom developed AF and 2 of whom
experienced cardiac arrest. Those with symptoms or AF
were younger and had a shorter accessory pathway refractory
period and multiple accessory pathways. The authors con-
cluded that in asymptomatic patients with WPW syndrome,
electrophysiologic testing might be a valuable tool for
identifying patients at risk of developing symptomatic
arrhythmias and possibly sudden death. Thus, it may be
warranted to perform electrophysiologic testing even in
asymptomatic WPW patients and then to perform ablation
to eliminate accessory pathway conduction in those at risk.
Pulmonary vein ablation for AF. Pappone et al. (40)
compared the clinical course of 589 patients who underwent
pulmonary vein isolation using radiofrequency catheter ab-
lation for AF with that of 582 patients who underwent
medical therapy, from a total of 1,171 consecutive patients
referred for treatment. After a median of 900 days of
follow-up, Kaplan-Meier analysis showed a statistically
significant advantage of pulmonary vein ablation over med-
ical therapy for recurrence of AF, all-cause mortality, and
morbidity due to congestive HF and ischemic cerebrovas-
cular events. Quality-of-life assessment reached normal
values at six-month follow-up and remained normal up to
one year, in contrast to medically treated patients. Thus, this
study raises the remarkable possibility that pulmonary vein
ablation may not only cure AF, but may also improve quality
of life and reduce morbidity and mortality. These findings
suggest the need for a large, randomized trial of pulmonary
vein ablation for atrial versus medical therapy.
Genetic model of cardiac hypertrophy and WPW syn-
drome. Recent studies have demonstrated that several dif-
ferent missense mutations in PRKAG2, the gene for the two
regulatory subunits of adenosine monophosphate-activated
protein kinase, may cause cardiac disease characterized by
conduction disorders and WPW syndrome, both with and
without ventricular hypertrophy. Berul et al. (41) demon-
strated in a transgenic mouse model that a clinical pheno-
type consistent with cardiac hypertrophy and pre-excitation
syndrome (WPW) could be produced by overexpression of
a mutant human gene. By week four after birth, seven of
eight mice with mutant deoxyribonucleic acid (DNA) de-
veloped pre-excitation patterns on the electrocardiogram
(ECG). Electrophysiologic testing revealed that mice ex-
pressing the mutant human gene, but not wild-type, had
evidence of atrioventricular (AV) connections separate from
the AV node. These accessory connections could be blocked
by procainamide, whereas adenosine produced AV block in
wild-type mice but not in those with mutant DNA and
accessory connections. Histologic examination revealed ev-
idence of a myocardial connection through the annulus
fibrosum in mutant but not wild-type mice. Thus, although
this study did not reveal the molecular mechanism by which
mutant Asn488Ile human PRKAG2 complementary DNA
resulted in the development of accessory AV connections
similar to those observed in humans with the same muta-
tion, it did establish a potentially useful model for studying
such mechanisms in the future.
Microvolt T-wave alternans to predict ventricular tachy-
arrhythmia. Hohnloser et al. (42) prospectively followed
137 patients with DCM for a period of 14  6 months for
three main end points: 1) sudden death, 2) resuscitated
ventricular fibrillation, and 3) hemodynamically unstable
ventricular tachycardia. Patients were risk-stratified for
these end points during the follow-up using noninvasive
tests, including: microvolt T-wave alternans, LV ejection
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fraction, baroreflex sensitivity, heart rate variability, pres-
ence of nonsustained ventricular tachycardia, signal-
averaged ECG, and presence of intraventricular conduction
defect. During follow-up, a total of 18 patients (13%)
developed one of the prespecified study end points. Statis-
tical analysis revealed that microvolt T-wave alternans and
baroreflex sensitivity were univariate predictors of the oc-
currence of any arrhythmic end points, but multivariate
Cox regression analysis indicated that only microvolt
T-wave alternans was a significant independent predictor
of risk. Thus, this study provides evidence that nonin-
vasive risk stratification may be useful in patients with
DCM, as opposed to ischemic cardiomyopathy, to identify
those at risk of life-threatening ventricular arrhythmia in
whom prophylactic treatment, including amiodarone or
implantable-cardioverter defibrillator placement, may be
warranted.
Prevalence of AF. Tsang et al. (43) evaluated a resident
population, reviewing demographic and medical data span-
ning a 30-year period, for evidence of a change in the
prevalence of AF. A total of 1,871 (mean age 75 years)
stroke cases and matched controls were evaluated. For
stroke cases, age-adjusted estimates of AF prevalence for the
years 1960 to 1969, 1970 to 1979, and 1980 to 1989 were
11%, 13%, and 16%, respectively, for men, and 13%, 16%,
and 20%, respectively, for women. For controls, the rates
were 5%, 8%, and 12%, respectively, for men, and 4%, 6%,
and 8%, respectively, for women. An increasing prevalence
of AF was observed to be associated with increasing age,
calendar time (after adjusting for age), and gender. The
rates of increase with calendar time were similar between
the genders. The authors concluded that the prevalence of
AF increased significantly in ischemic stroke patients and
controls from 1960 to 1989, and that this increase was
independent of both age and gender. These findings are of
interest because they suggest that the apparent epidemic of
AF in this country may not be entirely due to increased
diligence on the part of physicians and the public to
diagnose or detect AF. Rather, for as yet unknown epide-
miologic reasons, there may actually be a greater prevalence
(and probably incidence) of AF in the U.S. population today
than that observed over the past four decades, not just due
to our aging population.
CARDIAC THERAPEUTICS
Aspirin resistance. Aspirin has antiplatelet effects that
reduce vascular events, but some patients are resistant to
aspirin, with unknown consequences. Gum et al. (44)
measured platelet aggregation in 326 patients with stable
cardiovascular disease and found a 5% incidence of aspirin
resistance. After a mean follow-up of two years, there was a
greater likelihood of death, MI, or cerebrovascular accident
in patients with aspirin resistance, compared with those
without aspirin resistance (24% vs. 10%). This prospective
trial demonstrated that aspirin resistance is not uncommon
and influences clinical outcomes. In an editorial, Eikelboom
and Hankey (45) noted it will be important to standardize
the criteria and methodology for defining aspirin resistance
to develop strategies to reduce thrombotic complications in
these patients.
Myoblast transplantation. Cell transplantation is a novel
experimental approach to replace lost cardiomyocytes after
MI to treat HF. Transplanting autologous skeletal muscle
myoblasts provides potential advantages, including the ease
of procuring an abundant number of cells that are resistance
to ischemia and rejection. Menasche et al. (46) tested the
feasibility and safety of this approach in a phase I human
trial. Myoblasts grown from thigh muscle biopsies were
injected into nonviable, akinetic LV scar tissue in 10
patients with LV dysfunction after MI. Two deaths oc-
curred unrelated to cell transplantation, and four patients
developed ventricular tachycardia that was managed with
automatic implantable-cardioverter defibrillators. There was
suggestion of improved regional and global LV function
over 11 months, although the trial was not designed to test
efficacy. Minami and Murry (47) note the importance of
this as the first clinical study to demonstrate the feasibility
and safety of transplanting skeletal myoblasts. This sets the
stage for future clinical trials to evaluate efficacy using this
novel approach.
Nitrate tolerance. Continuous exposure to organic ni-
trates, such as transdermal glyceryl trinitrate, attenuates its
therapeutic effectiveness. The mechanisms of nitrate toler-
ance may include impaired release of nitric oxide and
increased superoxide generation in the vascular endothelium
that may cause endothelial dysfunction. Muller et al. (48)
examined nitrate tolerance in an experimental study in
rabbits using isosorbide mononitrate with eccentric dosing
(twice a day) similar to that used clinically. Mild nitrate
tolerance developed at higher doses without increasing
vascular superoxide production or impairing endothelial
function. Thus, long-term therapy with this nitrate prepa-
ration can be used safely without aggravating endothelial
dysfunction. Horowitz (49) noted that the induction of
nitrate tolerance is nitrate-specific with variable effects on
oxidative stress and endothelial dysfunction. The efficacy of
nitrate therapy can be improved, while minimizing adverse
effects on endothelial function by understanding the mech-
anisms of nitrate tolerance.
Myocardial preconditioning. Brief episodes of myocardial
ischemia have protective effects against subsequent episodes
of ischemia, a phenomenon termed “preconditioning.” An
early phase of preconditioning that lasts for a few hours
occurs clinically. There is a late phase of preconditioning
that lasts for days, but this is not well established in humans.
Lambiase et al. (50) found that exercise-induced ischemia
triggers late preconditioning measured 24 h later in 30
patients with stable CAD. Preconditioning attenuated the
effects of exercise or PCI on ST-segment changes on the
ECG and was unrelated to changes in coronary collateral
flow. Thus, exercise (at levels sufficient to induce ischemia)
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has myocardial protective effects against subsequent epi-
sodes of ischemia for at least 24 h in humans.
Peroxisome proliferator-activated receptor (PPAR)-gamma
agonists. The thiazolidinediones, including rosiglitazone,
are insulin-sensitizing agents that target PPAR-gamma.
The PPAR-gamma agonists have anti-inflammatory effects,
including those on atherosclerotic plaques that express
PPAR-gamma, and attenuate endothelial dysfunction.
Sidhu et al. (51) investigated the potential benefits of
rosiglitazone in 84 patients with stable CAD without
diabetes mellitus. Compared with placebo, patients ran-
domized to receive rosiglitazone for 12 weeks exhibited
decreases in insulin resistance, markers of endothelial cell
activation (E-selectin, von Willebrand factor), and acute-
phase reactants (CRP and fibrinogen). Plutzky (52) noted
the emerging potential role of PPAR-alpha agonists to
target PPAR-alpha in vascular and inflammatory cells in
atherosclerosis, in addition to diabetes mellitus and insulin
resistance.
AGE AND CARDIAC DISEASE
CAD in young adults. Cole et al. (53) followed 843
patients under the age of 40 years old who were diagnosed
with CAD by coronary angiography for 15 years. They
concluded that coronary disease in young adults carries a
poor long-term prognosis and that previous MI, diabetes,
active tobacco abuse, and lower ejection fraction predicted
significantly higher mortality. In an accompanying editorial
comment, Klein and Nathan (54) noted that while the
incidence of MI and symptomatic CAD in young adults is
low, the consequences can be tragic. They also noted that
young adults with CAD have a rapidly progressive form of
the disease and that the traditional risk factors for CAD
generally lack a strong association in these patients.
Quality of life after cardiac surgery in the elderly. Two
articles in the October 2003 issue of JACC noted that
quality-of-life improvements in elderly patients were com-
parable to those observed in younger patients after two
different types of cardiac surgery.
AGE AND CARDIAC VALVE SURGERY. Sedrakyan et al. (55)
prospectively studied 148 patients with aortic valve proce-
dures and 72 patients with mitral valve procedures. They
concluded that in patients referred for cardiac valve surgery,
age does not appear to limit the quality-of-life benefits of
surgery. In an accompanying editorial, Rumsfeld (56) noted
that the primary implication of the study is that older
patients undergoing cardiac valve surgery have significant
improvements in quality of life, on par with the improve-
ments seen in younger patients.
THE ELDERLY: HEALTH STATUS BENEFITS AND RECOVERY
OF FUNCTION ONE YEAR AFTER CORONARY ARTERY BYPASS
GRAFT SURGERY. Conaway et al. (57) compared the health
status (symptoms, function, and quality of life) changes of
elderly patients undergoing coronary artery bypass graft
surgery to those of younger patients. They concluded that,
despite a slower rate of physical recovery, older patients
derived health status benefits from coronary artery bypass
graft surgery similar to those of younger patients. In an
accompanying editorial, Maurer (58) noted that age should
not be considered a non-modifiable risk for worse outcomes
and suggested that systems of care that address the possi-
bilities of poor outcomes for older patients should be
developed.
BASIC SCIENCE
Genetic polymorphisms affect the severity of atheroscle-
rosis. Traditional risk factors for atherosclerosis such as
dyslipidemia, diabetes, hypertension, and smoking account
for only a portion of the risk burden for atherosclerosis.
Therefore, as we enter the genomic era of risk stratification,
considerable effort has been applied toward identification of
polymorphisms in the human genome that increase the risk
for atherosclerosis. Single nucleotide polymorphisms are
small genetic variations that can occur commonly (present
in 0.5% to 1% of the population) within an individual’s
DNA sequence. Single nucleotide polymorphisms are dis-
tinct from and more common than a mutation where there
is a change in a wild-type gene itself.
Given the large number of genes that could contribute to
atherosclerosis and the polygenic nature of the disorder, it is
a challenge to determine which of many polymorphisms are
causally linked to disease. Glutamate-cysteine ligase is a
rate-limiting enzyme for synthesis of glutathione that plays
a crucial role in the intracellular antioxidant defense sys-
tems. Kugiyama et al. (59) demonstrated in a modest
number of patients that a polymorphism in the glutamate-
cysteine ligase catalytic subunit gene was associated with an
increased risk of MI. Importantly, the authors also demon-
strated that this polymorphism in the promoter region of
the gene altered binding of a nuclear protein to the
promoter, affected the expression of the gene, and had a
functional effect on acetylcholine-induced coronary artery
vasodilation. Although additional analysis with larger and
more genetically diverse populations will be required to
confirm the significance of these findings, this article dem-
onstrates the importance of combining functional analysis of
a polymorphism with population studies to determine
which of the many polymorphisms that are identified are
important in the pathogenesis of atherosclerotic disease.
Role for adenovirus infection in patients of all ages with
myocarditis and DCM. Infectious myocarditis and DCM
have been associated with a number of different viruses, but
coxsackievirus has been the most extensively studied. Tow-
bin et al. (60) tested for the presence of a broad range of
viruses from 624 patients with myocarditis and 149 patients
with DCM using reverse transcription polymerase chain
reaction or just polymerase chain reaction. Both pediatric
and adult patients were evaluated. They demonstrated that
238 of the samples (38%) were positive for at least one virus.
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Of these, 142 samples were positive for adenoviral DNA,
whereas 85 sample were positive for coxsackieviral ribonu-
cleic acid. They also demonstrated that adenoviral DNA
was present in samples from patients of all ages.
As pointed out by Baboonian and McKenna in the
accompanying editorial (61), these findings are interesting
from the perspective that the receptor for both viruses is the
coxsackie-adenoviral receptor, indicating an important role
for the interaction between coxsackie-adenoviral receptor
and viruses that most commonly cause myocarditis. In
addition, it indicates the probable importance of an under-
recognized cause of myocarditis and DCM (i.e., adenoviral
infection). Future mechanistic and therapeutic strategies for
viral heart disease should consider these results.
CARDIAC IMAGING
Identification of multivessel CAD. A drawback of myo-
cardial perfusion single-photon emission computed tomog-
raphy (SPECT), or MPS, techniques is that patients with
ischemia in multiple coronary territories often do not
manifest perfusion defects in all ischemic territories due to
the competitive nature of SPECT perfusion defect assess-
ment. Lima et al. (62) hypothesized that by combining
perfusion and function measurements with gated SPECT
(Fig. 1 in Lima et al. [62]), identification of patients with
multivessel perfusion abnormalities can be enhanced. These
investigators studied 143 patients with angiographic three-
vessel CAD and 112 control subjects. The MPS results were
interpreted sequentially—first perfusion data only, followed
by combined perfusion and function data. In patients with
angiographic three-vessel CAD, the combination of perfu-
sion and function data identified significantly more abnor-
mal segments/patient (6.2  4.7 vs. 4.1  2.8, p  0.001)
and more defects in multiple vascular territories (60% vs.
46%, p  0.05) than perfusion alone. On the other hand,
there were no differences between the combined perfusion/
function and perfusion alone interpretations in the control
group. Multivariate modeling revealed patient age and the
number of vascular territories determined to be abnormal by
either perfusion or function analysis as the most powerful
predictors of three-vessel CAD. This study established that
functional data yielded incremental information over and
above that yielded by clinical and perfusion data for pre-
dicting the presence of three-vessel CAD.
Risk after normal perfusion SPECT. How long after a
normal MPS study patients remain at low risk has yet to be
examined. Hachamovitch et al. (63) addressed this issue in
a study that identified 7,376 consecutive patients who had a
normal exercise or adenosine MPS study. Over a mean
follow-up of 1.8 years (96% complete), 78 hard events
occurred, for an overall cumulative rate of 1.1%, or 0.6%/
year in patients with a negative MPS. Significant increases
in hard-event rates occurred in diabetic women, CAD
patients undergoing exercise stress, and patients undergoing
adenosine stress. Importantly, with respect to exercise stress,
hard-event rates were higher in patients who achieved
80% of the predicted maximum heart rate. Cox propor-
tional hazards analysis identified pharmacologic stress,
known previous CAD, diabetes mellitus, male gender, and
increasing age as the most significant predictors of hard
events.
With respect to time and risk, in patients without
previous CAD, the predicted risk increased significantly
with age, with the presence of diabetes mellitus in women,
and with adenosine stress. For any combination of clinical
factors, the level of risk in these patients appeared to stay
uniform year after year. However, for any combination of
clinical factors in patients with known CAD, the risk
increased with time. Hence, although a normal MPS study,
in general, confers low risk, certain patient characteristics
result in greater risk. The accelerating temporal character-
istics of risk in patients with known CAD are probably
explained by the CAD itself, whereas the majority of
patients without known CAD who are found to have a
normal MPS most likely do not have CAD.
Effect of beta-blockade on dipyridamole MPS. Although
it is well recognized that beta-blockers blunt the effects of
exercise on MPS, whether these agents exert a similar effect
on dipyridamole MPS is less well studied. Taillefer et al.
(64) performed a prospective, double-blinded, placebo-
controlled study in 21 patients with angiographically docu-
mented CAD. All patients underwent three dipyridamole
sestamibi SPECT studies after intravenous placebo and
low- and high-dose intravenous metoprolol. The sensitivity
of dipyridamole MPS for detection of CAD was 86% with
placebo versus 71% with low- and high-dose metoprolol.
The sensitivity for detecting CAD in individual vessels was
69% with placebo versus 52% with metoprolol; the summed
stress score was larger after placebo compared with either
dose of metoprolol (p  0.05). In an accompanying edito-
rial, Gerson (65) ascribed the effect to an improvement of
subendocardial flow secondary to the negative inotropic and
chronotropic effects of the beta-blocker and suggested that
cautious withdrawal of patients from beta-blockers before
dipyridamole MPS should be considered.
Combined life-style and pharmacologic lipids. The ef-
fects of aggressive medical management on myocardial
perfusion and long-term outcomes were addressed by Sdrin-
gola et al. (66). They studied 324 patients undergoing
dipyridamole myocardial perfusion positron emission to-
mography (PET) before and 2.6 years after the institution of
medical therapy and repeated the PET study five years after
the second scan. A maximal treatment group received
intense life-style modification, including a diet containing
10% fat and exercise, as well as aggressive treatment of
low- and high-density lipoprotein cholesterol; a moderate
treatment group was treated with lipid-lowering drugs or
dietary restriction, but not to the goals of the maximal
group; a poor treatment group (n  92) was actively
smoking or not on a lipid reduction regimen. Patients in the
maximal treatment group showed a significant improvement
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in the size/severity of perfusion abnormalities, whereas
those in the moderate and poor treatment groups showed
worsening of PET perfusion. Over the subsequent five-year
follow-up, revascularization, MI, and cardiac death occurred
in 6.6%, 20.3%, and 30.6% of the maximal, moderate, and
poor treatment groups, respectively. By multivariate analy-
sis, multiple clinical variables, including combined intense
life-style change plus active lipid drugs, initial PET find-
ings, and degree of PET improvement, were independent
predictors of cardiac events. As editorialized by Parmley
(67), although not a randomized clinical trial, this study
provides evidence of the benefit of aggressive medical and
life-style management on long-term outcomes and is also
one of the largest studies to date demonstrating that
improvement of stress myocardial perfusion on medical
therapy is predictive of this benefit.
Delayed enhancement by magnetic resonance in hyper-
trophic cardiomyopathy (HCM). Patients suffering a sud-
den cardiac death with HCM are known to have increased
myocardial fibrosis. Delayed hyperenhancement on cardiac
magnetic resonance after gadolinium injection has been
shown to be a sensitive and specific marker of myocardial
necrosis or fibrosis. Moon et al. (68) studied 53 patients
with HCM, 23 of whom had two or more clinical markers
of high risk for sudden death or had demonstrated progres-
sive LV remodeling. Myocardial hyperenhancement was
found in 42 patients, involving a mean of 10.9% of the LV
mass, and was more extensive with progressive remodeling
and in patients with a high risk of sudden death. This study,
in combination with a study by Kim et al. (69), provides
evidence that the unique capability of hyperenhancement
cardiac magnetic resonance to define myocardial necrosis/
fibrosis may be useful in assessing risk in HCM patients.
Pending confirmation in larger trials, these findings may
improve the identification of a subgroup of HCM patients
warranting consideration of an implantable-cardioverter
defibrillator to prevent sudden cardiac death.
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